Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol in Pediatric CKD Subjects With Iron Deficiency Anemia
NCT03619850Phase 3Recruiting
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Aug 2018
- Primary completion
- Aug 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of ferumoxytol in iron deficiency anemia (IDA) (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Hemoglobin change of at least 0.5 g/dL at Week 5. Started Aug 2018; status: recruiting.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03619850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619850.